12 results
10-K
2019 FY
GRTX
Galera Therapeutics Inc
10 Mar 20
Annual report
7:36am
to patients;
the product may become less competitive; and
our reputation may suffer.
Any of the foregoing events could prevent us from achieving … develop;
injury to our reputation and significant negative media attention;
regulatory investigations that could require costly recalls or product
10-Q
2019 Q3
GRTX
Galera Therapeutics Inc
10 Dec 19
Quarterly report
7:31am
; and
our reputation may suffer.
Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular … candidates that we may develop;
injury to our reputation and significant negative media attention;
regulatory investigations that could require costly
424B4
oar0h3l0h978osu
8 Nov 19
Prospectus supplement with pricing info
4:41pm
S-1/A
s4yw7t4 4r
28 Oct 19
IPO registration (amended)
7:16am
S-1
ezoakg 6bsqoxisz
11 Oct 19
IPO registration
5:27pm
DRS/A
pfzfpi ujr17c
12 Sep 19
Draft registration statement (amended)
12:00am
DRS/A
lcfr1k
9 Aug 19
Draft registration statement (amended)
12:00am
DRS/A
dlghsy zae5v1
23 Apr 19
Draft registration statement (amended)
12:00am
DRS
u4fugqya2
15 Mar 19
Draft registration statement
12:00am
- Prev
- 1
- Next